StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Wednesday. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald reissued an overweight rating and issued a $2.50 price target on shares of VolitionRx in a research note on Thursday, May 16th.

VolitionRx Stock Down 4.0 %

VNRX stock opened at $0.64 on Wednesday. The company has a 50 day moving average of $0.67 and a two-hundred day moving average of $0.81. The company has a market cap of $52.77 million, a price-to-earnings ratio of -1.38 and a beta of 1.13. VolitionRx has a 12-month low of $0.55 and a 12-month high of $1.38.

VolitionRx (NYSE:VNRX) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. On average, research analysts anticipate that VolitionRx will post -0.31 EPS for the current year.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.